InvestorsHub Logo
Followers 5
Posts 566
Boards Moderated 0
Alias Born 04/25/2013

Re: None

Thursday, 03/02/2017 8:46:40 AM

Thursday, March 02, 2017 8:46:40 AM

Post# of 108192
Update on the Phase 3 AIM2CERV study in locally advanced cervical cancer and the company’s oral, late-breaker presentation on axalimogene filolisbac on March 14 is the only data on pharmacotherapeutic interventions being presented for cervical cancer during SGO’s Annual Meeting.



The trial must be going great! They giving updates already.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News